Aiming to eliminate unnecessary complexity
The manufacture and release of mRNA therapeutics and vaccines is a complex and challenging process that requires a high degree of expertise, capabilities, and experience. The production process involves several stages, including the production of cell banks, linear DNA, mRNA drug substance, LNP encapsulation, fill/finish, and analytical testing at each step. Each production stage must be executed with extreme care to ensure the final product's safety and efficacy.
Furthermore, when working with multiple contract development and manufacturing organizations (CDMOs), the management of logistics, tech transfer, release testing, shipping, storage, and analytical testing becomes complex and requires intense project management.
Aldevron has overcome this challenge by offering a comprehensive mRNA production ecosystem with sequence-to-vial capabilities under one-roof and quality system, thereby eliminating the unnecessary complexities of multiple CDMO exchanges while accelerating the program timeline.
As part of the rollout of our new mRNA services, Todd Howren, Vice President of RNA Client Services, provided an exclusive overview of the system at the TIDES USA conference in Boston. The presentation is now available for viewing and for you to share with your colleagues.
- Visit our mRNA Production web page
- Want to learn more about this topic? Contact Todd Howren
- Read more about our vial-to-sequence mRNA services, from Yasser Kehail
- Have an idea for a topic? Let us know!